288 related articles for article (PubMed ID: 24173694)
1. Olanzapine is effective for refractory chemotherapy-induced nausea and vomiting irrespective of chemotherapy emetogenicity.
Vig S; Seibert L; Green MR
J Cancer Res Clin Oncol; 2014 Jan; 140(1):77-82. PubMed ID: 24173694
[TBL] [Abstract][Full Text] [Related]
2. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
Natale JJ
Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy-induced nausea and vomiting.
Lohr L
Cancer J; 2008; 14(2):85-93. PubMed ID: 18391612
[TBL] [Abstract][Full Text] [Related]
4. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Navari RM; Nagy CK; Gray SE
Support Care Cancer; 2013 Jun; 21(6):1655-63. PubMed ID: 23314603
[TBL] [Abstract][Full Text] [Related]
5. Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine.
Bosnjak SM; Dimitrijevic J; Djordjevic F
Curr Opin Support Palliat Care; 2016 Jun; 10(2):180-8. PubMed ID: 27028050
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
7. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a retrospective study.
Chiu L; Chiu N; Chow R; Zhang L; Pasetka M; Stinson J; Lechner B; Pulenzas N; Verma S; Chow E; DeAngelis C
Ann Palliat Med; 2016 Jul; 5(3):172-8. PubMed ID: 27199269
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis.
Chiu L; Chow R; Popovic M; Navari RM; Shumway NM; Chiu N; Lam H; Milakovic M; Pasetka M; Vuong S; Chow E; DeAngelis C
Support Care Cancer; 2016 May; 24(5):2381-2392. PubMed ID: 26768437
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting: a meta-analysis.
Yang T; Liu Q; Lu M; Ma L; Zhou Y; Cui Y
Br J Clin Pharmacol; 2017 Jul; 83(7):1369-1379. PubMed ID: 28112422
[TBL] [Abstract][Full Text] [Related]
10. A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients.
Fonte C; Fatigoni S; Roila F
Crit Rev Oncol Hematol; 2015 Aug; 95(2):214-21. PubMed ID: 25779971
[TBL] [Abstract][Full Text] [Related]
11. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature.
Chow R; Herrstedt J; Aapro M; Chiu L; Lam H; Prsic E; Lock M; DeAngelis C; Navari RM
Support Care Cancer; 2021 Jul; 29(7):3439-3459. PubMed ID: 33442782
[TBL] [Abstract][Full Text] [Related]
12. Olanzapine Reduces Chemotherapy-induced Nausea and Vomiting Compared With Aprepitant in Myeloma Patients Receiving High-dose Melphalan Before Stem Cell Transplantation: A Retrospective Study.
Trifilio S; Welles C; Seeger K; Mehta S; Fishman M; McGowan K; Strejcek K; Eiten E; Pirotte C; Lucier E; DeFrates S; Mehta J
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):584-589. PubMed ID: 28694084
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review.
Chow R; Chiu L; Navari R; Passik S; Chiu N; Popovic M; Lam H; Pasetka M; Chow E; DeAngelis C
Support Care Cancer; 2016 Feb; 24(2):1001-1008. PubMed ID: 26530228
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting.
Navari RM
Biomed Res Int; 2015; 2015():595894. PubMed ID: 26421294
[TBL] [Abstract][Full Text] [Related]
15. Olanzapine in the treatment of refractory nausea and vomiting: a case report and review of the literature.
Langley-DeGroot M; Ma JD; Hirst J; Roeland EJ
J Pain Palliat Care Pharmacother; 2015 Jun; 29(2):148-52. PubMed ID: 26095486
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.
Abe M; Hirashima Y; Kasamatsu Y; Kado N; Komeda S; Kuji S; Tanaka A; Takahashi N; Takekuma M; Hihara H; Ichikawa Y; Itonaga Y; Hirakawa T; Nasu K; Miyagi K; Murakami J; Ito K
Support Care Cancer; 2016 Feb; 24(2):675-682. PubMed ID: 26130365
[TBL] [Abstract][Full Text] [Related]
17. Olanzapine as antiemetic drug in oncology: a retrospective study in non-responders to standard antiemetic therapy.
Slimano F; Netzer F; Borget I; Lemare F; Besse B
Int J Clin Pharm; 2018 Oct; 40(5):1265-1271. PubMed ID: 29744791
[TBL] [Abstract][Full Text] [Related]
18. Emerging Role of Olanzapine for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting.
DeRemer DL; Clemmons AB; Orr J; Clark SM; Gandhi AS
Pharmacotherapy; 2016 Feb; 36(2):218-29. PubMed ID: 26890915
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation.
Nakagaki M; Barras M; Curley C; Butler JP; Kennedy GA
Support Care Cancer; 2017 Feb; 25(2):607-613. PubMed ID: 27738796
[TBL] [Abstract][Full Text] [Related]
20. QoL evaluation of olanzapine for chemotherapy-induced nausea and vomiting comparing with 5-HT3 receptor antagonist.
Liu J; Tan L; Zhang H; Li H; Liu X; Yan Z; Chen J; Yang H; Zhang D
Eur J Cancer Care (Engl); 2015 May; 24(3):436-43. PubMed ID: 25404537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
